HC Wainwright Reaffirms Buy Rating for Arcus Biosciences (NYSE:RCUS)

Arcus Biosciences (NYSE:RCUS)‘s stock had its “buy” rating reiterated by HC Wainwright in a note issued to investors on Monday,Benzinga reports. They presently have a $32.00 price objective on the stock. HC Wainwright’s target price indicates a potential upside of 42.67% from the company’s previous close. HC Wainwright also issued estimates for Arcus Biosciences’ Q1 2026 earnings at ($1.01) EPS, Q2 2026 earnings at ($1.05) EPS, Q3 2026 earnings at ($1.09) EPS, Q4 2026 earnings at ($1.04) EPS, FY2026 earnings at ($4.66) EPS, FY2027 earnings at ($3.62) EPS, FY2028 earnings at ($2.26) EPS, FY2029 earnings at ($0.71) EPS and FY2030 earnings at $0.30 EPS.

A number of other research analysts also recently commented on the stock. Truist Financial set a $30.00 price objective on shares of Arcus Biosciences in a research report on Friday, December 12th. Wells Fargo & Company set a $23.00 price target on Arcus Biosciences and gave the stock an “equal weight” rating in a report on Thursday, February 12th. Morgan Stanley reissued an “equal weight” rating and set a $20.00 price target (down from $23.00) on shares of Arcus Biosciences in a research report on Thursday, January 8th. Citigroup reaffirmed a “buy” rating on shares of Arcus Biosciences in a research report on Friday, December 12th. Finally, Wall Street Zen upgraded Arcus Biosciences from a “sell” rating to a “hold” rating in a research note on Saturday. Eight investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $31.30.

Arcus Biosciences Stock Down 6.3%

RCUS stock opened at $22.43 on Monday. The company has a market cap of $2.81 billion, a price-to-earnings ratio of -6.80 and a beta of 0.85. Arcus Biosciences has a twelve month low of $6.50 and a twelve month high of $26.40. The business has a 50 day moving average price of $21.57 and a two-hundred day moving average price of $18.74. The company has a quick ratio of 4.36, a current ratio of 4.36 and a debt-to-equity ratio of 0.16.

Arcus Biosciences (NYSE:RCUS) last released its quarterly earnings data on Wednesday, February 25th. The company reported ($0.89) EPS for the quarter, beating the consensus estimate of ($1.11) by $0.22. Arcus Biosciences had a negative return on equity of 65.77% and a negative net margin of 142.91%.The company had revenue of $33.00 million during the quarter, compared to the consensus estimate of $24.94 million. During the same quarter in the prior year, the firm posted ($1.03) EPS. The firm’s revenue for the quarter was down 8.3% compared to the same quarter last year. Analysts anticipate that Arcus Biosciences will post -3.15 EPS for the current fiscal year.

Insider Transactions at Arcus Biosciences

In other news, President Juan C. Jaen sold 82,997 shares of the stock in a transaction that occurred on Thursday, December 4th. The stock was sold at an average price of $24.71, for a total transaction of $2,050,855.87. Following the transaction, the president owned 954,063 shares in the company, valued at approximately $23,574,896.73. This trade represents a 8.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, COO Jennifer Jarrett sold 11,225 shares of the business’s stock in a transaction on Tuesday, December 16th. The shares were sold at an average price of $21.88, for a total value of $245,603.00. Following the completion of the sale, the chief operating officer owned 203,007 shares of the company’s stock, valued at $4,441,793.16. This trade represents a 5.24% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 263,987 shares of company stock worth $6,025,620 over the last three months. Company insiders own 9.60% of the company’s stock.

Institutional Investors Weigh In On Arcus Biosciences

Institutional investors have recently modified their holdings of the business. GAMMA Investing LLC grew its stake in shares of Arcus Biosciences by 59.1% in the third quarter. GAMMA Investing LLC now owns 2,748 shares of the company’s stock valued at $37,000 after acquiring an additional 1,021 shares in the last quarter. Hantz Financial Services Inc. boosted its holdings in Arcus Biosciences by 121.9% in the 4th quarter. Hantz Financial Services Inc. now owns 1,604 shares of the company’s stock valued at $38,000 after purchasing an additional 881 shares during the period. SBI Securities Co. Ltd. grew its position in shares of Arcus Biosciences by 13,547.6% during the 3rd quarter. SBI Securities Co. Ltd. now owns 2,866 shares of the company’s stock worth $39,000 after purchasing an additional 2,845 shares in the last quarter. T. Rowe Price Investment Management Inc. acquired a new position in shares of Arcus Biosciences during the 4th quarter worth approximately $39,000. Finally, CWM LLC increased its holdings in shares of Arcus Biosciences by 233.6% during the second quarter. CWM LLC now owns 5,441 shares of the company’s stock worth $44,000 after purchasing an additional 3,810 shares during the period. Institutional investors own 92.89% of the company’s stock.

Arcus Biosciences Company Profile

Arcus Biosciences is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel cancer immunotherapies. The company’s research platform centers on modulating tumor microenvironments and immune checkpoints through both small-molecule and antibody-based candidates. Arcus aims to enhance antitumor immune responses by targeting pathways such as the adenosine axis and inhibitory receptors on immune cells.

The company’s lead clinical programs include etrumadenant, an orally administered A2A adenosine receptor antagonist being evaluated in combination with anti-PD-1 therapy, and domvanalimab, an anti-TIGIT monoclonal antibody.